Invokana a Growing concern for Janssen

Introduction

J&J's Janssen Pharmaceuticals has more than 800 product liability cases across the nation for its anti-diabetic drug Invokana. This news is confirmed by J&J's quarterly financial filing with the Securities and Exchange Commission (SEC). The Invokana cases are consolidated as a part of an MDL before U.S. District Judge Brian Martinotti in the District of New Jersey and the trials for a small number of bellwether cases are expected to begin in September 2018. Apart from this, several federal cases are pending in the Southern District of California and the Eastern District of Missouri, as well as state court cases, are pending in California, New Jersey, and Pennsylvania. Allegations mainly involve kidney failure, heart attacks, and diabetic ketoacidosis, with a recent addition of increased risk of leg or foot amputations following a warning released by the FDA in May 2017.

Comments

Walgreens Settles Federal Opioid Case for $300 Million

Categories: Opioids

Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.

The U.S. Department of Justice announced on Monday…

Study: Opioid Use in Pregnancy May Shrink Newborn Brains

Categories: Opioids

New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…

Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting

Categories: Opioids

The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…

Invokana a Growing concern for Janssen